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Expressional alterations in functional
ultra-conserved non-coding rnas in response to
all-trans retinoic acid - induced differentiation in
neuroblastoma cells
Karen M Watters1,2*, Kenneth Bryan1,2, Niamh H Foley1,2, Maria Meehan1,2 and Raymond L Stallings1,2
Abstract
Background: Ultra-conserved regions (UCRs) are segments of the genome (≥ 200 bp) that exhibit 100% DNA
sequence conservation between human, mouse and rat. Transcribed UCRs (T-UCRs) have been shown to be
differentially expressed in cancers versus normal tissue, indicating a possible role in carcinogenesis. All-trans-retinoic
acid (ATRA) causes some neuroblastoma (NB) cell lines to undergo differentiation and leads to a significant
decrease in the oncogenic transcription factor MYCN. Here, we examine the impact of ATRA treatment on T-UCR
expression and investigate the biological significance of these changes.
Methods: We designed a custom tiling microarray to profile the expression of 481 T-UCRs in sense and anti-sense
orientation (962 potential transcripts) in untreated and ATRA-treated neuroblastoma cell lines (SH-SY5Y, SK-N-BE,
LAN-5). Following identification of significantly differentially expressed T-UCRs, we carried out siRNA knockdown
and gene expression microarray analysis to investigate putative functional roles for selected T-UCRs.
Results: Following ATRA-induced differentiation, 32 T-UCRs were differentially expressed (16 up-regulated, 16
down-regulated) across all three cell lines. Further insight into the possible role of T-UC.300A, an independent
transcript whose expression is down-regulated following ATRA was achieved by siRNA knockdown, resulting in the
decreased viability and invasiveness of ATRA-responsive cell lines. Gene expression microarray analysis following
knockdown of T-UC.300A revealed a number of genes whose expression was altered by changing T-UC.300A levels
and that might play a role in the increased proliferation and invasion of NB cells prior to ATRA-treatment.
Conclusions: Our results indicate that significant numbers of T-UCRs have altered expression levels in response to
ATRA. While the precise roles that T-UCRs might play in cancer or in normal development are largely unknown and
an important area for future study, our findings strongly indicate that the function of non-coding RNA T-UC.300A is
connected with proliferation, invasion and the inhibition of differentiation of neuroblastoma cell lines prior to ATRA
treatment.
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Background
Neuroblastoma (NB) is a highly heterogenous childhood
cancer that arises from precursor cells of the sympathetic
nervous system [1]. Clinical behaviour of these tumors,
ranging from spontaneous regression to rapid progression
and death due to disease, is highly correlated with a num-
ber of genomic alterations involving ploidy, MYCN ampli-
fication (MNA), and large-scale genomic imbalances such
as loss of chromosome 1p, 3p, 11q and gain of 17q. MNA
and loss of heterozygosity on chromosome 11q are par-
ticularly associated with aggressive disease course and rep-
resent independent genetic subtypes of NB. Each genetic
subtype of NB, such as MNA or 11q-, also has significant
differences in the expression patterns of large sets of pro-
tein coding genes [2-6], and in the expression profiles of
non-coding RNAs such as microRNAs [7-11].
Ultra-conserved regions (UCRs) are by definition DNA
segments that are at least 200 bp in length and that are
100% conserved between human, rat and mouse genomes.
Four hundred and eighty-one such regions have been
identified [12]. UCRs are comprised of three basic types –
intragenic (39%), intronic (43%) and exonic (15%), which
also includes ‘partly exonic’ and ‘exon containing’. Ap-
proximately 3% of UCRs are not easily classified, due to
their juxtaposition with alternative splice variants of host
genes and the resulting variable annotation. Calin et al.
[13] carried out the first analysis of transcribed UCRs
(T-UCRs) in cancer, demonstrating that approximately
9% of the 962 possible T-UCRs (sense + anti-sense) were
aberrantly transcribed in either carcinomas or leukemias
relative to normal tissue. Most significantly, the authors fur-
ther demonstrated that siRNA-mediated down-regulation
of one T-UCR (T-UC.73A) significantly increased apoptosis
in a colorectal cancer cell line. Two recent studies have
demonstrated that analysis of UCR expression signatures
can also be applied to the evaluation of NB tumors [14,15].
Differential UCR expression profiles were shown to be
associated with outcome in short-term versus long-term
survivors with high-risk, stage 4 NB [15]. In addition,
Mestdagh et al., found an expression signature of up-
regulated T-UCRs in MNA compared to non-MNA
tumors [14].
The synthetic retinoic acid, 13-cis-retinoic acid, is an
established component of the treatment given to children
with high-risk NB to reduce minimal residual disease
[16,17] and exposure of a number of NB cell lines, such as
SK-N-BE, to ATRA induces neural cell differentiation
along with down-regulation of MYCN [18]. Here, we iden-
tify T-UCRs that are responsive to the retinoid, all-trans-
retinoic acid (ATRA), across three ATRA-sensitive cell
lines and investigate the functional role of the deregulated
transcript T-UC.300A.
Previous studies analyzing UCR expression in NB have
used qPCR, involving reverse transcription with random
primers, which is unable to distinguish between transcripts
originating from the sense or the anti-sense genomic
strand. Our approach involved the construction of tiling
arrays for 962 UCR regions, allowing for the detection of
both sense and anti-sense transcripts and for expression of
host genes. We identified and validated a number of T-
UCRs that are differentially expressed following ATRA-
induced differentiation. Further insight into a functional
role for T-UC.300A was achieved by siRNA knockdown
resulting in the decreased viability and invasiveness
of ATRA-responsive cell lines. As T-UC.300A is down-
regulated following ATRA treatment, our findings strongly
indicate that its function is connected with the increased
proliferation and invasion of NB cells prior to ATRA-
treatment.
Methods
Cell culture
The NB cell lines SK-N-BE and SH-SY5Y were obtained
from the American Type Culture Collection (ATCC). Cell
culture medium consisted of Ham’s F12 and EMEM
(50:50) supplemented with fetal bovine serum (10%), non-
essential amino acids (0.5%), L-glutamine (0.5%) and peni-
cillin/streptomycin (1%). The LAN-5 cell line was obtained
from the Children’s Oncology Group Repository. LAN-5
culture medium consisted of RPMI supplemented with
penicillin/streptomycin (1%). All cell culture reagents were
obtained from GIBCO.
ATRA treatment
All-trans retinoic acid (ATRA) was administered daily
(5 μM final conc.) to cells over a period of 7 days. Treated
and untreated cells were fixed using 4% paraformaldhyde
(Sigma) and permeabilised in 0.5% Triton X-100. Cells
were probed using the neuronal marker βIII Tubulin
(Abcam), and subsequently were incubated with the
flourescein-conjugated goat anti-rabbit Alexa Flour 488
antibody (Invitrogen). Cells were washed in PBS and then
counterstained using DAPI. The Nikon TE2000s Fluore-
scence microscope was used to examine the cells and
photographs were taken with the Hamamatsu (Orca 285)
CCD Camera.
Microarray design
The UCR custom tiling microarray was developed using
Roche NimbleGens 4 × 72 K array, composed of four
identical subarrays, tiling 962 ultra-conserved sequences
(481 sequences in both sense and anti-sense orientation).
Oligo lengths ranged from 50mer to 72mer, in order to
maintain a similar Tm across all probes. The genomic
coordinates of the 481 UCRs (Build HG17, May 2004)
were obtained from http://users.soe.ucsc.edu/~jill/ultra.
html and converted to Build HG18, using UCSC’s Batch
Coordinate Conversion tool (http://genome.ucsc.edu/
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cgi-bin/hgLiftOver). In addition to the ultra-conserved
sequences themselves, tiling coverage also spanned 2500
bases upstream and 500 bases downstream of the location
of each UCR on both sense and anti-sense strands. Probes
were designed in two separate containers (sense and anti-
sense) on each subarray to facilitate independent data ana-
lysis. Array design is available in ArrayExpress– Accession
number A-MEXP-1899.
For gene expression, the Homo Sapiens 4 × 72 K gene
expression array from Roche NimbleGen was used.
Sample preparation
The QIAGEN RNeasy Mini Kit (Cat. No. 74101) was used
to extract RNA from cells (untreated at Day 0 and ATRA-
treated at Day 7). DNase treatment was included to ensure
complete removal of any genomic DNA that could affect
results by also hybridising to the microarrays. RNA integ-
rity was confirmed with the Agilent RNA Nano 6000 kit
(Cat. No. 5067–1511) and an Agilent Bioanalyzer. Only
RNA with an RNA Integrity Number (RIN) of >8 was used
for microarray analysis. For tiling microarrays, double-
stranded cDNA was synthesised from 3 ug total RNA
using the ExpressArt TRinucleotide mRNA Amplification
Micro Kit (AmpTec). In vitro transcription using the
ExpressArt AminoAllyl Add-on Module (AmpTec) gener-
ated aminoallyl modified-anti-sense RNA (aRNA), which
was subsequently incubated with NHS-Cy3 (Amersham).
Following purification, 4 μg Cy3-aRNA was hybridised to
microarrays.
For gene expression microarray analysis following siRNA
knockdown of T-UC.300A or ATRA treatment, sample
preparation was carried out as previously described [19].
RT-PCR
Reverse transcription for transcribed UCRs was carried
out on 1ug total RNA with gene-specific primers and
the SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen) in a total reaction volume of 20 ul
(T-UC.324: 50 CCCCATCCCATATGACACTC 30; T-UC
.300A: 50 AAAAGTGGAAATCAATTTTGAAGG 30).
Real-time PCR was carried out using custom designed
TaqMan assays for T-UC.324 and T-UC.300A (Applied
Biosystems).
Western blot
Total protein was isolated from cells using a radio-
immunoprecipitation assay (RIPA) lysis buffer (Sigma).
Cell pellets were washed with PBS and solubilized in
RIPA for 30 mins. Protein concentration was measured
using the BCA assay from Pierce. Proteins were frac-
tionized on 6% or 10% polyacrylamide gels, and blotted
onto nitrocellulose membrane. MYCN protein and the
neuronal marker β – III Tubulin were detected by
Western Blot using the mouse monoclonal antibody SC-
53993 (Santa Cruz) and the rabbit polyclonal antibody
AB-8191 (Abcam) respectively.
siRNA knockdown
siRNAs against T-UC.324 and T-UC.300A were designed
using Dharmacons siRNA Design Centre. siRNAs were
as follows:
T-UC.324: TTACCTAACCAGTGATTAA
(sense strand sequence)
T-UC.300A: ATTCATGGATGGAGATTGA
(sense strand sequence)
Cells were transfected with T-UCR siRNAs (final con-
centration 50 nM) or negative control siRNA (Dharmacon
Negative Control #1, final concentration 50 nM) using the
transfection reagent Lipofectamine (Invitrogen). Media
was changed after 24 hrs. RNA was extracted 120 hrs after
transfection.
Acid phosphatase assay
Cells were transfected with siRNAs in 96-well plates using
Lipofectamine, and plates were set up for timepoints 24-
120 hrs. At each timepoint, the appropriate plate was
washed twice with PBS. 10 mM p-nitrophenol phosphate
in 0.1 M sodium acetate with 0.1% triton X-100 was
added. Plates were incubated at 37°C for two hours and
the reaction was stopped with 50 μL 1 M sodium hydrox-
ide per well. Absorbance was measured at 405 nm using
the Victor X3 Multi-Label Reader (Perkin Elmer).
Cell proliferation assay
The effect of siRNA knockdown of T-UC.300A on the rate
of cell proliferation in SH-SY5Y cells was assayed using
the Cell Proliferation ELISA, BrdU (colorimetric) kit
(Roche, Cat. No. 11 647 229 001). Cells were transfected
with siRNA against T-UC.300A or a scrambled control
and were cultured in a tissue culture grade, flat bottom
96-well plate for 96 hours (n=4). BrdU labeling solution
was added to each well (final concentration 10 μM BrdU)
and the cells were re-incubated for an additional 2 hours.
The labeling medium was then removed and the cells
were fixed and denatured. Denatured DNA was incubated
with an anti-BrdU monoclonal antibody conjugated with
peroxidase for 90 minutes, followed by washing. 100 μl/
well substrate solution was added and the plate was incu-
bated at +15 to +25°C for 5 minutes. Stop solution (25 μl
1M H2SO4) was added to each well and mixed thoroughly.
Absorbance of samples was measured using the Victor X3
Multi-Label Reader (Perkin Elmer) at 450 nm, reference
wavelength 690 nm. Following subtraction of the absorb-
ance value for the blank control from all readings, the
change in proliferation rate induced by knockdown of T-
UC.300A was determined.
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Invasion assays
Cells were transfected in a 6-well plate. 48 hours after
transfection, cells were trypsinized and counted. 2.5×104
cells were added to BD BioCoat™ Growth Factor Reduced
MATRIGEL™ Invasion Chambers (BD Biosciences) as per
manufacturers’ instructions and incubated for a further
72 hrs. To determine the average number of invading
cells, MATRIGEL inserts were stained with crystal violet
and viewed under the microscope. The number of cells/
field, in 5 random fields were counted at 200× magnifica-
tion. Mean values of duplicate experiments were calcu-
lated and results subjected to t-test.
Data processing and bioinformatics analysis
Gene expression arrays
ThemRNA expression data was analysed using NimbleGens
NimbleScan software version 2.4, which applied quantile
normalization to the data [20] and expression values were
obtained using the Robust Multi-Chip Average algorithm as
described by Irizarry et al. [21]. Expressional alterations of
1.5 fold across both biological repeats were considered
significant.
T-UCR tiling arrays
Microarrays were scanned using the GenePix 4000B
scanner. Pair reports were generated using NimbleGen’s
NimbleScan software version 2.4, and normalised by ap-
plying quantile normalisation. Median smoothing was first
carried out on both the forward and reverse T-UCR tiling
arrays with a window of 3 probes to remove outlying
probe values. T-UCRs were considered expressed if their
mean probe value was above the array background (me-
dian expression of the array). Only T-UCRs that were
expressed in all 3 cell lines were considered. T-UCRs that
were differentially expressed at least 1.5 fold in 2 out of 3
cell lines (n ≥ 4) were selected. For these selected T-UCRs,
p-values were calculated across all 3 cell lines (n=6 bio-
logical samples) using Student’s t-test, and only T-UCRs
with a p-value < 0.05 were considered significant.
Correlation of intragenic t-ucrs and host gene expression
Using the expression data from the ATRA-treated and
untreated tiling arrays, intragenic T-UCRs transcribed in
the same directions as their host genes were assessed for
independent transcription relative to exonic expression,
if exons were covered by the tiled region. Pearson’s cor-
relation of T-UCR expression (mean probe value) and
gene (mean expression of exonic probes) over experi-
mental samples was used to assess T-UCR/Host gene ex-
pression correlation. Significance of this correlation was
determined from a table of critical values for Pearson’s
Correlation over various degrees of freedom.
Cluster analysis of intragenic t-ucrs expression
T-UCR expression was measured on the forward and
reverse strand however this causes problems when cal-
culating object similarity in cluster analyses i.e. every ob-
ject will be represented twice in the expression dataset
by two independent features sets, one on the forward
strand and one on the reverse strand. The matrix was
Figure 1 T-UCRs expressed following ATRA-treatment. Thirty-two T-UCRs were differentially expressed following ATRA-induced differentiation
of neuroblastoma cell lines with p<0.05, with 16 transcripts up-regulated and 16 down-regulated greater than 1.5 fold in at least 4/6 samples. The
red boxes indicate the two T-UCRs selected for PCR validation and functional analysis.
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Table 1 T-UCRs altered by ATRA
T-UCR name SK-N-BE
(n=2)
LAN-5
(n=2)
SH-SY5Y
(n=2)
Type Orientation with host gene Host gene UCR_host correlation Previously reported data p-value
uc.324 5.57 2.68 9.86 Exon anti-sense MPPED2 0.0019
uc.127a 2.02 2.12 1.57 Intergenic 0 0 0.0026
uc.75 1.86 2.66 1.77 Exon anti-sense ZEB2 0.0030
uc.345a 2.02 2.37 1.92 Intron anti-sense HOXC4 0.0066
uc.409 2.29 2.45 2.33 Intergenic 0 0 FRA<2MB (Calin et al., 2007) 0.0107
uc.109 3.58 2.16 3.52 Intron anti-sense LOC375295 HOX cluster (Calin et al., 2007) 0.0123
uc.113a 2.46 2.48 1.33 Intergenic 0 0 0.0134
uc.465a 2.62 1.89 1.63 Intron anti-sense POLA1 0.0154
uc.344 1.41 2.86 3.38 Intron sense HOXC4 Sig. correlated FRA<2MB (Calin et al., 2007) 0.0156
uc.359a 5.08 2.35 1.33 Exon sense NOVA1 Sig. correlated 0.0194
uc.198a 1.31 2.25 2.76 Intergenic 0 0 0.0204
uc.206 1.14 2.01 2.24 Intergenic 0 0 0.0245
uc.217 1.25 2.39 2.44 Exon sense VSTM2A Sig. correlated 0.0256
uc.451 1.15 3.01 4.67 Intron anti-sense TSHZ3 0.0297
uc.341a 1.28 4.54 1.92 Exon anti-sense HOXC10 FRA<2MB (Calin et al., 2007) 0.0303
uc.396 1.11 3.77 1.75 Intergenic 0 0 Down-regulated in HCC (Calin et al., 2007) 0.0346
uc.481a 0.38 0.41 0.33 Exon anti-sense STAG2 0.0005
uc.195a 0.50 0.38 0.21 Intron sense C6orf167 No data available 0.0013
uc.49a 0.48 0.66 0.29 Exon sense FAM98A No data available Inferred role in differentiation for UCR49
(Mestdagh et al., 2010)
0.0082
uc.449 0.42 0.49 0.64 Intron sense ZNF536 No data available 0.0086
uc.203 0.18 0.47 0.59 Exon sense QKI Sig. correlated LOH (Calin et al., 2007) 0.0097
uc.48 0.31 0.75 0.31 Exon anti-sense PUM2 0.0109
uc.419a 0.35 0.78 0.36 Exon sense SFRS1 Not Correlated FRA<2MB, HPV16<2.5MB (Calin et al., 2007) 0.0125
uc.50a 0.35 0.68 0.27 Intron sense SFRS7 Sig. correlated 0.0131
uc.300a 0.38 0.51 0.79 Intron anti-sense PAX2 LOH, HOX gene, Up-regulated in CRC
(Calin et al., 2007)
0.0135
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Table 1 T-UCRs altered by ATRA (Continued)
uc.284 0.81 0.09 0.14 Intergenic 0 0 0.0138
uc.48a 0.37 0.59 0.48 Exon sense PUM2 No data available 0.0160
uc.243 0.59 0.27 0.67 Intron sense ZFHX4 Not correlated AMPLIF (Calin et al., 2007) 0.0176
uc.163 0.59 0.41 0.51 Intergenic 0 0 0.0179
uc.388 0.28 0.75 0.47 Intron sense TCF12 No data available Up-regulated in CRC (Calin et al., 2007)
Down-regulated in CRC (Sana et al., 2012)
0.0202
uc.97 0.55 0.65 0.28 Intron sense HAT1 Not correlated HOX gene (Calin et al., 2007) 0.0307
uc.82a 0.40 0.37 0.99 Intergenic 0 0 0.0499
Table shows the mean fold change across two samples for each cell line following ATRA treatment. 32 T-UCRs showed significantly altered expression following ATRA treatment across all samples (p<0.05).
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re-ordered by first re-orientating the arbitrary direction
of T-UCR expression so that it was relative to the host
gene with sense (S) referring to those T-UCRs tran-
scribed with the host gene and anti-sense (A) referring
to those T-UCRs transcribed in the opposite direction to
the host gene. The S and A expressions for each T-UCR
were then merged into a single feature set, thus the data
matrix of 962 and F expression features was converted into
a data matrix of 481 T-UCRS and 2F features (FS + FA).
Similarity of expression of intragenic T-UCRs was then
determined using Spearman’s rank correlation. Hierar-
chical clustering was subsequently carried out using
Ward’s metric and presented with accompanying heatmap
visualization. Analysis was carried out using algorithms
implemented in Java v1.6 and packages from R statistical
programming language R version 2.8.0.
Results
In order to examine the expression levels of all T-UCRs,
a custom array was designed tiling across all UCRs on
both plus and minus genomic strands. Thus, a potential
962 T-UCRs, transcribed from 481 genomic regions
when taking into account forward and reverse tran-
scripts, could be detected. Tiling also incorporated 2500
bases upstream and 500 bases downstream of each UCR.
Discernment of the genomic strand from which each T-
UCR originated was possible by synthesizing anti-sense
RNA (aRNA), which is complementary to the original
transcript, for Cy3 labelling and array hybridization.
Differential expression of t-ucrs following atra treatment
In order to identify putative T-UCRs involved in neuro-
blastoma cell differentiation, three ATRA-sensitive NB
cell lines, SK-N-BE (n=2), LAN-5 (n=2) and SH-SY5Y
(n=2), were treated daily with ATRA for 7 days, which
resulted in extensive neurite outgrowth. Differentiation
was also confirmed at protein level through the observed
up-regulation of the differentiation marker TUBB3 and
down-regulation of MYCN (Additional file 1: Figure S1).
Expression analysis using the tiling arrays identified 32
transcripts whose expression was significantly altered
(p<0.05) following ATRA-induced differentiation (fold
change of ≥1.5 in at least 4 out of the 6 biological re-
peats) (Figure 1, Table 1). The array results were
Figure 2 T-UCR-host gene correlation. Intragenic T-UCRs were
assessed for correlative expression relative to host gene exonic
expression, if exons were covered by the tiled region. (A) Box plots
showing correlations between intragenic T-UCR expression and host
gene expression. Anti-sense intronic T-UCRs displayed the lowest
correlation with host genes, and sense exonic T-UCRs displayed the
highest. The expression of anti-sense intronic T-UCRs (B) T-UC.350
and (C) T-UC.90 is significantly anti-correlated with the expression of
their host genes DACH1 and TBR1 respectively (p<0.05).
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Figure 3 Functional analysis of T-UCRs. T-UC.324 and T-UC.300A transcripts were knocked down using custom designed siRNA (Dharmacon).
(A) Knockdown of T-UC.324 significantly abrogated its up-regulation following ATRA-treatment, (B) but had no effect on cell viability. (C) A
significant decrease in T-UC.300A levels was observed following siRNA transfection. (D) Knockdown of T-UC.300A resulted in a decrease in cell
invasion as shown by MATRIGEL invasion assay (p<0.01) and (E) cell viability as shown by acid phosphatase assay (P<0.01). (F) Reduction in cell
viability following T-UC.300A knockdown was shown by BrdU assay to be due to a decrease in cell proliferation (p<0.05). (G) Knockdown of
neither T-UC.324 nor T-UC.300A had any effect on apoptosis.
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validated by qPCR for selected T-UCRs using custom
designed TaqMan assays (Additional file 2: Figure S2).
The up-regulation of T-UC.324 was confirmed in all
three cell lines. Levels of T-UC.300A could not be
detected by qPCR in SK-N-BE, however its down-
regulation was validated in both SH-SY5Y and LAN-5.
The intergenic T-UCRs (9/32) can be considered inde-
pendent transcripts as they are not embedded in protein
coding host genes. Among the intragenic T-UCRs, 10
were transcribed in the opposite direction to their host
gene, and therefore also represent independently tran-
scribed ncRNAs. For the partially exonic or intronic T-
UCRs that were expressed in a sense direction with their
host gene, at least 3 likely represent independent tran-
scripts as their level of expression is not significantly
correlated with the host exon expression (e.g. host gene
down-regulated in response to ATRA while T-UCR is
up-regulated and vice versa). The correlation of T-UCR
/host gene expression could only be carried out for in-
tragenic T-UCRs that had host gene exons within their
surrounding tiled regions (2500 bp upstream and 500 bp
downstream of each UCR). Exonic T-UCRs expressed in
the sense direction relative to their host gene had the
highest correlations with their host genes (median cor-
relation = 0.68), with 67% showing a significant correl-
ation (p<0.05). Intronic T-UCRs expressed anti-sense to
their host gene displayed the lowest correlation with
their host genes (median correlation = 0.13), with just
12% showing a significant correlation (p<0.05) (Figure
2A; Additional file 3: Table S1). In summary, 22 independ-
ent non-coding transcriptional units that were responsive to
ATRA could be identified, while 5 ATRA responsive in-
tronic or exonic T-UCRs were identified whose expression
was significantly correlated with their host genes. Consistent
with these findings, some of the T-UCR host genes, such as
HOXC4, are known to be responsive to ATRA [22].
Investigation of regulation through transcriptional
interference
Independent intragenic T-UCRs, either sense or anti-sense,
could be involved in the regulation of their host genes
through different types of transcriptional interference -
where transcriptional elongation has a direct, cis-acting
suppressive effect on a second transcriptional process [23].
Analysis of all intragenic T-UCRs and their host gene ex-
pression revealed seven T-UCRs whose expression was sig-
nificantly anti-correlated with that of their host gene
(Additional file 3: Table S1). None of the seven T-UCRs
showed a consistent change in expression across cell lines
following ATRA-treatment, however in individual samples
T-UCR expression was significantly anti-correlated with
host gene expression (p<0.05) which might suggest a form
of regulation through transcriptional interference. The
anti-correlation between T-UC.350 and T-UC.90 and their
host genes can be seen in Figure 2B, C. Of particular inter-
est is the T-UC.350/DACH1 anti-correlation. DACH1 is a
tumor suppressor gene, whose expression is reduced in
prostate and endometrial cancer correlating with increased
tumor progression and invasion [24,25]. The significant
anti-correlation seen here between the two transcripts
(p<0.05) suggests a possible cis regulation between the two
in different cancer types.
siRNA knockdown and functional analysis of t-uc.300a
The prioritization of differentially expressed T-UCRs
for functional assessment was based on the statistical
Table 2 Top 15 up- and down-regulated protein coding
genes following siRNA knockdown of T-UC.300A in SH-
SY5Y cells
Gene name Mean fold change
T-UC.300A siRNA knockdown
Mean fold
change after ATRA
INPP5D 3.72
CALCA 3.67 40.16
LOC221442 3.24
LOC644242 3.23 5.28
TTC9B 2.94 2.18
GDF15 2.93 5.10
USP9X 2.78
COL1A2 2.75
C10orf85 2.70
FLJ4184 2.62
HBE1 2.53
DPF3 2.44
LOC402199 2.43 37.41
FLJ44635 2.42 1.65
KLF2 2.38
RAB27B 0.35
FLJ44124 0.37
CNTNAP5 0.07
PAX5 0.38
INHBA 0.39
PCDHGA10 0.39
TOR1AIP2 0.39 0.23
CHR4155SYT 0.39
ZNF718 0.40
PRTG 0.41
HOOK1 0.41 0.38
LOC643647 0.42 0.59
LOC643523 0.42
IPMK 0.42
ERCC4 0.43
Table shows fold change following knockdown across two biological repeats
and also the corresponding mean fold change following ATRA if present.
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Figure 4 (See legend on next page.)
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significance of differential expression between untreated
and ATRA-treated cells, in addition to other features of
interest such as proximity to cancer-associated genomic
regions or deregulation in other cancer types. The tran-
script of most interest from our list was T-UC.300A,
which is down-regulated following ATRA treatment
(Table 1). This UCR is located within a frequent loss of
heterozygosity (LOH) region on chromosome arm 10q,
anti-sense to the developmental gene PAX2, a gene
whose under- or over-expression is associated with both
pediatric and adult kidney pathology [26]. In addition, T-
UC.300A levels were previously shown as up-regulated
in colorectal carcinoma tumors [13]. Considering its
down-regulation in ATRA-treated neuroblastoma cells,
this suggests that T-UC.300A could play a role in both
pediatric and adult cancers. T-UC.324 was selected as
our second T-UCR for functional analysis. The most
significantly up-regulated transcript across the three
ATRA-treated cell lines (p=0.002) (Table 1, Figure 1), this
ncRNA is expressed anti-sense to the Mpedd2 gene, which
displays an anti-tumorigenic function in differentiated NB
cells and is also highly expressed [27]. Both T-UC.324 and
T-UC.300A are independent transcripts, and not tran-
scribed as part of a host gene.
SH-SY5Y and LAN-5 cells were transfected with custom
designed siRNAs against either T-UC.324 or T-UC.300A
to knock down these transcripts and assess any effect of
this knockdown on cell invasion and proliferation rates.
Knockdown of T-UC.324 abrogated its ATRA-induced
up-regulation by 40% to 60% (Figure 3A) and effected a
small but significant relief from the decrease in cell proli-
feration induced by ATRA (p<0.05) (Figure 3B). Although
this effect was statistically significant across biological
repeats, it was minimal and considered unlikely to con-
tribute to any major biological role. However, knockdown
of T-UC.300A resulted in a more significant decrease
(p<0.01) in cell viability (Figure 3C, D). Using the Cell
Proliferation ELISA, BrdU (colorimetric) kit (Roche), we
determined that this decrease in cell viability was the re-
sult of a down-regulation in cell proliferation (Figure 3E),
as opposed to an increase in apoptosis (Figure 3G). In
addition, knockdown of the T-UC.300A transcript resulted
in a decrease in cell invasion (p=0.008) (Figure 3F). There
was no obvious change in cell morphology following
knockdown. As T-UC.300A is significantly down-regulated
following ATRA treatment, this reduction in both prolifer-
ation and invasion rates seen with siRNA knockdown
supports a role for this transcript in the inhibition of differ-
entiation, and as a promoter of proliferation and invasion.
Gene expression microarray analysis of SH-SY5Y cells
following siRNA knockdown of T-UC.300A (n=2) was
carried out in an effort to identify any protein-coding
genes which may be involved in T-UC.300A promotion
of proliferation and invasion, or inhibition of differenti-
ation prior to ATRA treatment. Following siRNA knock-
down of T-UC.300A, 150 genes were up-regulated and
123 genes were down-regulated (at least 1.5 fold in both
biological repeats). The genes with the greatest mean
fold change are listed in Table 2. qPCR was carried out
on COL1A2 to validate array results (Additional file 4:
Figure S3). By comparing the differentially expressed
genes with genes we have previously shown to be altered
by ATRA in SH-SH5Y cells (n=2) [19], we found that 46
out of the 150 genes up-regulated following T-UC.300A
knockdown were also up-regulated following ATRA
treatment (at least 1.5 fold, n=2). In addition, 23 genes
down-regulated following siRNA knockdown were also
down-regulated following ATRA treatment. These re-
sults suggest that the altered expression of these genes fol-
lowing ATRA could be the result of changing T-UC.300A
levels.
Unsupervised analysis of T-UCR expression
In order to determine if T-UCRs had sub-groupings with
characteristic expression behaviour, unsupervised ana-
lysis was performed on the intragenic T-UCR cell line
expression profiles. The T-UCR data was pre-processed
as described in the Methods section.
From the heatmap in Figure 4, we see that sub-groups
of intragenic T-UCRs are expressed in three main clus-
ters. Cluster 1 and Cluster 2 represent T-UCRs that are
expressed in the anti-sense and sense direction, respect-
ively, relative to the host gene transcription in a manner
largely independent of cell line or treatment. Another
subset (Cluster 3) is expressed in a more variable fashion
over samples and treatments. This latter subset is signifi-
cantly enriched for DNA binding proteins (P=2.9e-02)
and has a significant under-representation of both RNA
binding proteins (P=6.6e-04) and of exonic T-UCRs
(P=6.0e-06). This suggests that certain sub-groups
(present in Clusters 1 and 2) T-UCRs may be transcribed
exclusively in a either a sense or anti-sense direction
relative to the host gene whereas another subset T-
(See figure on previous page.)
Figure 4 Unsupervised analysis of intragenic T-UCR cell line expression profiles. Subgroups of T-UCRs are expressed in three main clusters:
Cluster 1, T-UCRs that are expressed anti-sense to the host gene expression; Cluster 2, T-UCRs that are expressed sense to host gene expression;
Cluster 3, T-UCRs that are expressed both sense and anti-sense to host gene expression and show a significant over-representation of DNA
binding proteins within their host genes relative to the other two clusters. Intragenic T-UCRs that are altered by ATRA are indicated with their
host gene on the right side of the heatmap.
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UCRs (present in Cluster 3) may be transcribed in both
directions relative to host gene.
Discussion
This study represents the first profiling and functional
analysis of transcribed long ultra-conserved ncRNAs that
are differentially expressed during ATRA induced diffe-
rentiation of NB cell lines. Although their 100% homology
between human, mouse and rat denotes possible critical
roles in vertebrate development, there has been limited
investigation of their roles in cancer development
[13-15,28,29]. Here we sought to identify and investigate
the functionality of T-UCRs differentially expressed in NB
cell lines following ATRA-treatment. We have identified a
role for T-UC.300A in the promotion of proliferation and
invasion of NB cells prior to ATRA-induced differenti-
ation. This intronic transcript is anti-sense to the develop-
mental transcription factor PAX2, a gene whose function
is essential during embryonic development and morpho-
genesis but whose overexpression also contributes to the
pathogenesis of diseases such as renal cell carcinoma and
medulloblastoma [30,31]. There is an emerging role for
ncRNAs in the regulation of HOX genes both in cis,
through the process of transcription itself, and in trans
through a direct role in gene regulation such as chromatin
re-modelling [32,33]. The repressive role of T-UC.300A
was alleviated by siRNA knockdown arguing against a role
for transcriptional interference and, indicating that this
ncRNA most likely exerts its effect in trans. PAX2 expres-
sion was not detected in either ATRA-treated or untreated
cells, also supporting a trans-acting role for T-UC.300A.
Gene expression microarray analysis showed that 150
genes were up-regulated following T-UC.300A knock-
down, 46 of which were also up-regulated by ATRA
treatment. The gene with the greatest increase in expres-
sion, INPP5D, encodes the SH2-containing inositol
phosphatase 1 (SHIP1), a negative regulator of the PI3K/
AKT pathway. Gene transfer of INPP5D has been shown
to reduce proliferation in CD34+ cells from patients
with acute myeloid leukemia (AML) [34]. A number of
the commonly differentially expressed genes are of par-
ticular interest in identifying a putative pathway for T-
UC.300A function. At least two of the most highly up-
regulated genes (CALCA, KLF2) have been reported as
hypermethylated in a number of cancers, including
neuroblastoma [35-38]. In addition, KLF2 is involved in
the inhibition of proliferation and migration and is si-
lenced in cancer by the Polycomb repressive complex 2
protein EZH2 [39,40]. Furthermore KLF2 expression in
acute promyelocytic leukemia (APL) can be restored by
ATRA treatment [41]. A recent study has shown that
overexpression of the long ncRNA HOTAIR altered
PRC2 occupancy in breast cancer cells [42]. With this in
mind, it is possible that the corresponding up-regulation
of genes such as KLF2, CALCA and COL1A2 following
knockdown of T-UC.300A could be indicative of a role
for this T-UCR in chromatin re-programming possibly
by targeting methylation–associated complexes such as
PRC2. Therefore reduced T-UC.300A levels (either by
siRNA or ATRA treatment) could co-ordinate the de-
repression of these genes by reducing methylation at
their promoters and explain the observed increase in
gene expression.
Our results show that the expression of a number of
T-UCRs is altered by ATRA-induced differentiation.
However it is clear that a number of mechanisms are at
work in their regulation, and consequently in the down-
stream regulation of T-UCR targets themselves.
Additional files
Additional file 1: Figure S1. Untreated and ATRA-treated SK-N-BE cells.
Cells were treated with ATRA (5μM final concentration) daily for 7 days.
(A) Cells were probed using the neuronal marker βIII Tubulin (Abcam),
and were incubated with the flourescein-conjugated goat anti-rabbit
Alexa Flour 488 antibody (Invitrogen). (B) Western Blot for ßIII-Tubulin,
MYCN and α-Tubulin (loading control) in untreated and ATRA-treated
cells.
Additional file 2: Figure S2. qPCR validation of tiling array results.
Array results were validated for T-UC.324 and T-UC.300A by qPCR using
gene-specific RT primers and custom-designed TaqMan Assays. Error bars
represent standard deviation from the mean across at least two
biological repeats.
Additional file 3: Table S1. Correlation of intragenic T-UCR and host
gene expression. T-UCRs are in four groups: exonic sense; exonic anti-
sense; intronic sense; intronic anti-sense. Shaded cells denote significance
or approaching significance.
Additional file 4: Figure S3. qPCR validation of gene expression
results. Gene expression microarray results were validated by qPCR for
COL1A2 in SHSY5Y cells following knockdown of T-UC.300A. Figure
shows results from array and from qPCR analysis. Error bars represent
standard deviation from the mean across two biological repeats.
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